Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.54 |
| ▸ | SELL | P14151 | 9/20 | 0.50 |
| ▸ | SELP | P16109 | 9/20 | 0.50 |
| ▸ | SELE | P16581 | 5/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9981032 | 0.98 | NOD1 (0.55) | NOD1SELLSELPSELEFOLH1 | |
| SCHEMBL619960 | 0.89 | CA2 (0.53) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL6413427 | 0.89 | CA2 (0.53) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL6413425 | 0.89 | CA2 (0.53) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL1636628 | 0.89 | CA2 (0.53) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL19326364 | 0.85 | FOLH1 (0.58) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19695690 | 0.85 | NOD1 (0.54) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL15846449 | 0.85 | NOD1 (0.54) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL15847221 | 0.85 | NOD1 (0.54) | NOD1FOLH1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL15846812 | 0.85 | NOD1 (0.54) | NOD1FOLH1RIMKLANAALAD2PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2525809-B1 | GLUCAGON-GLP1 DUAL AGONISTS FOR USE IN THE TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA AS (DK) | 2016-08-03 | — | — | EP | claimed |
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-05-05 | — | — | US | claimed |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-01-07 | — | — | US | claimed |
| EP-2454282-B1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2015-03-04 | — | — | EP | claimed |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2014-01-09 | — | — | US | claimed |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | claimed |
| US-20120178670-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2012-07-12 | — | — | US | claimed |
| EP-2585482-B1 | GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2019-03-27 | — | — | EP | disclosed |
| US-20190076506-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2019-03-14 | — | — | US | disclosed |
| US-10004786-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2018-06-26 | — | — | US | disclosed |
| EP-2525809-B1 | GLUCAGON-GLP1 DUAL AGONISTS FOR USE IN THE TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA AS (DK) | 2016-08-03 | — | — | EP | disclosed |
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-05-05 | — | — | US | disclosed |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-01-07 | — | — | US | disclosed |
| EP-2454282-B1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2015-03-04 | — | — | EP | disclosed |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2014-01-09 | — | — | US | disclosed |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | disclosed |
| US-20130157929-A1 | GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2013-06-20 | — | — | US | disclosed |
| US-20120178670-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| EP-2454282-A1 | ACYLATED GLUCAGON ANALOGUES | Zealand Pharma A/S (DK) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006497-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | NOD1 1032/4885SELL 1618/4885SELP 2803/4885 |
| US-10004786-B2 | Acylated glucagon analogues | GLP1R, GCGR, GIPR | NOD1 1016/4885SELL 1695/4885SELP 2869/4885 |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | IAPP, GLP1R, GCG | NOD1 1995/4885SELL 1520/4885SELP 4336/4885 |
| US-20190076506-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | NOD1 1032/4885SELL 1618/4885SELP 2803/4885 |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | IAPP, GLP1R, GCG | NOD1 1995/4885SELL 1520/4885SELP 4336/4885 |
| US-20120178670-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | NOD1 1032/4885SELL 1618/4885SELP 2803/4885 |
| US-20130157953-A1 | TREATMENT OF CARDIAC CONDITIONS | GLP1R, GCGR, TNNT2 | NOD1 1889/4885SELL 1395/4885SELP 2204/4885 |
| US-20130157929-A1 | GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | NOD1 429/4885SELL 1271/4885SELP 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.